A leishmaniose visceral (LV) é uma doença crônica e potencialmente fatal causada, no Brasil, pelo protozoário Leishmania infantum. A resistência à LV é relacionada ao desenvolvimento de uma resposta imune celular eficiente. Para isso, células dendríticas (DCs) reconhecem produtos antigênicos do parasito, através dos Toll-like Receptors (TLRs), e, após ativação, produzem fatores, que irão orquestrar o recrutamento celular e desenvolvimento da resposta imune protetora. Dentre os vários TLRs, tem sido demonstrado que o TLR9 está relacionado com a resistência à infecção em modelo de leishmaniose cutânea. No presente estudo, nosso objetivo foi determinar o papel do TLR9 durante a infecção por L. infantum. Nossos resultados demonstram que a expressão de TLR9 é modulada positivamente durante a infecção in vivo e in vitro pela L. infantum. O TLR9 é essencial para o controle da infecção contra L. infantum, uma vez que camundongos TLR9-/- são mais susceptíveis à infecção, apresentando maior número de parasitos no baço e fígado na 4ª e 6ª semana pós-infecção. A fenotipagem de leucócitos presente no baço demonstrou que camundongos TLR9-/- possuem menor número de neutrófilos. De maneira semelhante, a análise imuno-histoquímica mostrou uma reduzida marcação de células 7/4+ (específica para neutrófilos) no fígado de animais TLR9-/-. A falha na migração de neutrófilos observada em animais TLR9-/- não está associada a uma incapacidade de ativação dos polimorfonucleares, mas sim a deficiências na produção de fatores quimiotáticos, como CXCL1 (KC) e CXCL2 (MIP-2) nos órgãos-alvo. Investigando o mecanismo de ação, as células dendríticas oriundas de animais TLR9-/- falham em seu processo de ativação frente à infecção in vitro e in vivo com L. infantum, apresentando um fenótipo semi-maduro, com redução de expressão de MHC-II e moléculas coestimuladoras. Interessante que essas células apresentaram deficiência na produção de mediadores quimiotáticos de neutrófilos como KC e MIP-2, e consequentemente, induzindo o menor recrutamento de neutrófilos in vitro. Em conjunto, nossos resultados demonstram que o TLR9 é essencial para o controle da infecção por L. infantum, através de um mecanismo dependente do recrutamento de neutrófilos para o sítio inflamatório mediado pela ativação apropriada de fatores quimiotáticos de neutrófilos pelas DCs. / Visceral leishmaniasis (VL) is a chronic and potentially fatal disease caused by protozoan Leishmania infantum, in Brazil. The resistance against VL is related to the development of cellular immune response. During infection, the dendritic cells (DCs) recognize antigenic products through Toll-like Receptors (TLRs) and then orchestrate the cellular recruitment and immune response development. Among several TLRs, it has been showed that TLR9 is related to resistance to cutaneous leishmaniasis. In the present study, our aim was to determinate the role of TLR9 during L. infantum infection. Our results demonstrated that TLR9 is up regulated during in vitro and in vivo L. infantum infection. TLR9 is critical for protective immunity against L. infantum, since TLR9-/- mice infected were more susceptible to infection, displaying high amounts of parasites in spleen and liver, at 4th and 6th weeks post-infection. Phenotyping the leukocytes into the spleen, TLR9-/- mice presented reduced neutrophils when compared to WT. Likewise, imunohistochemistry analyses showed the reduced of 7/4+ cells (specific to neutrophils) staining into the TLR-9-/- liver. The failure of neutrophil migration is not associated to their stage of activation impaired, but due the reduced levels of CXCL1 (KC) and CXCL2 (MIP-2) (neutrophil chemoatracttant) produced into into the spleen cells culture from infected TLR9-/-. Furthermore, DCs from TLR9-/- presented a semi-mature stage during in vitro and in vivo L. infantum infection, showing reduced expression of MHC-II and co-stimulatory molecule. Interestingly, the ability of DC to produce the neutrophil chemotact mediators (KC and MIP-2) was completely reduced by that derived from TLR9-/- mice, affecting neutrophil migration into Boyden chamber. Altogether, we demonstrated that TLR9 presents a critical role in the protective response against L.infantu through the mechanism dependent of crosstalk between neutrophil recruitment and DC activation.

BAFF, «facteur d'activation des lymphocytes B (LB) » contribue à l'expansion des LB autoréactifs de faible affinité lors de la mise en place de la tolérance. Cependant, les mécanismes menant à la surexpression de BAFF dans les maladies auto-immunes ne sont pas compris. Nous avons découvert un nouveau variant de BAFF, 4BAFF (dans lequel l'exon 4 est épissé), qui agit comme un facteur de transcription de son propre gène et participe à sa régulation. Ainsi, 4BAFF est préférentiellement observé dans les cellules isolées de patients atteints de maladies auto-immunes. De plus, 4BAFF régule un grand nombre de gènes associés à la réponse immunitaire innée et à la régulation de l’apoptose. Une autre constatation importante est que 4BAFF est un élément clé pour comprendre l’activité des LB régulateurs. Notre travail présente un concept entièrement nouveau suggérant qu'une cytokine peut être régulée par l'activité de l'un de ses variants d'épissage. Par ailleurs, nous avons observé que les cellules épithéliales expriment le récepteur de BAFF : BR3. Le blocage de BR3 se traduit par la translocation nucléaire de PKC et l'apoptose des cellules épithéliales. Par un effet autocrine, nous démontrons que seules certaines formes de BAFF participent à la survie des cellules épithéliales. Enfin , nous avons étudié les conséquences de l'expression du TLR9 à la surface des LB et démontrons que ce TLR9 membranaire ne fixe pas le CpG et agit comme un co-récepteur négatif du BCR. En effet, l'activation des LB par le CpG capté au niveau endosomal, est inhibée par l’action d’un anticorps anti-TLR9 se fixant au niveau membranaire. Tous ces résultats contribuent à une meilleure compréhension des mécanismes impliqués dans l'immunopathologie des maladies autoimmunes avec des applications potentielles en thérapeutique. / Elevated expression of ‘B cell activating factor’ (BAFF), a potent B cell survival factor contributes to the expansion of low-affinity self-reactive B cells during the establishment of tolerance. However, mechanisms leading to BAFF over-expression in autoimmune diseases are not understood. We reported the discovery of a new variant for BAFF, 4BAFF in humans (in which exon 4 is excised) or 5BAFF in mice (in which exon 5 is excised), which acts as a transcription factor of the full-length form of BAFF, and which is preferentially found in cells isolated from patients with autoimmune diseases. When transfected in human B cells, D4BAFF upregulates a large number of genes associated with immune response and especially innate immunity and regulation of apoptotis. Furthermore D4BAFF acts, in association with p50 from the NF- B pathway, as a transcription factor for its own parent gene. Another important finding is that 4BAFF is an important component of the efficacy of regulatory B cell activity. Our work introduces an entirely novel concept in biology suggesting that a human cytokine gene can be transcriptionally regulated by the activity of one of its own splice variants.We have also tried to understand the complexity of the various forms of BAFF. We observed that epithelial cells expressed BAFF-receptor (BR3) and produce BAFF suggesting autocrine properties. Blocking BR3 results in nuclear translocation of PKC promoting epithelial cell apoptosis.Furthermore, only some forms of BAFF are required for epithelial cell survival. Finally, we studied the consequences of the expression of TLR9 on the B cell surface and demonstrated that TLR9 acts as a co-receptor of the B cell receptor to influence B cell fate independently of CpG binding. We show that CpG activation of B cells, acting synergistically with BCR signals, was inhibited by anti-TLR9 stimulation. Induction of CD25 expression and proliferation of B cells were thus down-regulated by engagement of cell surface TLR9. Overall, our results indicate that TLR9 expressed on B cell plasma membrane might be a negative regulator of endosomal TLR9, and could provide a novel control by which activation of autoreactive B cells is restrained. All these findings contribute to a better understanding on immunopathology of autoimmune diseases with potential applications in therapy.

A leishmaniose visceral (LV) é uma doença crônica e potencialmente fatal causada, no Brasil, pelo protozoário Leishmania infantum. A resistência à LV é relacionada ao desenvolvimento de uma resposta imune celular eficiente. Para isso, células dendríticas (DCs) reconhecem produtos antigênicos do parasito, através dos Toll-like Receptors (TLRs), e, após ativação, produzem fatores, que irão orquestrar o recrutamento celular e desenvolvimento da resposta imune protetora. Dentre os vários TLRs, tem sido demonstrado que o TLR9 está relacionado com a resistência à infecção em modelo de leishmaniose cutânea. No presente estudo, nosso objetivo foi determinar o papel do TLR9 durante a infecção por L. infantum. Nossos resultados demonstram que a expressão de TLR9 é modulada positivamente durante a infecção in vivo e in vitro pela L. infantum. O TLR9 é essencial para o controle da infecção contra L. infantum, uma vez que camundongos TLR9-/- são mais susceptíveis à infecção, apresentando maior número de parasitos no baço e fígado na 4ª e 6ª semana pós-infecção. A fenotipagem de leucócitos presente no baço demonstrou que camundongos TLR9-/- possuem menor número de neutrófilos. De maneira semelhante, a análise imuno-histoquímica mostrou uma reduzida marcação de células 7/4+ (específica para neutrófilos) no fígado de animais TLR9-/-. A falha na migração de neutrófilos observada em animais TLR9-/- não está associada a uma incapacidade de ativação dos polimorfonucleares, mas sim a deficiências na produção de fatores quimiotáticos, como CXCL1 (KC) e CXCL2 (MIP-2) nos órgãos-alvo. Investigando o mecanismo de ação, as células dendríticas oriundas de animais TLR9-/- falham em seu processo de ativação frente à infecção in vitro e in vivo com L. infantum, apresentando um fenótipo semi-maduro, com redução de expressão de MHC-II e moléculas coestimuladoras. Interessante que essas células apresentaram deficiência na produção de mediadores quimiotáticos de neutrófilos como KC e MIP-2, e consequentemente, induzindo o menor recrutamento de neutrófilos in vitro. Em conjunto, nossos resultados demonstram que o TLR9 é essencial para o controle da infecção por L. infantum, através de um mecanismo dependente do recrutamento de neutrófilos para o sítio inflamatório mediado pela ativação apropriada de fatores quimiotáticos de neutrófilos pelas DCs. / Visceral leishmaniasis (VL) is a chronic and potentially fatal disease caused by protozoan Leishmania infantum, in Brazil. The resistance against VL is related to the development of cellular immune response. During infection, the dendritic cells (DCs) recognize antigenic products through Toll-like Receptors (TLRs) and then orchestrate the cellular recruitment and immune response development. Among several TLRs, it has been showed that TLR9 is related to resistance to cutaneous leishmaniasis. In the present study, our aim was to determinate the role of TLR9 during L. infantum infection. Our results demonstrated that TLR9 is up regulated during in vitro and in vivo L. infantum infection. TLR9 is critical for protective immunity against L. infantum, since TLR9-/- mice infected were more susceptible to infection, displaying high amounts of parasites in spleen and liver, at 4th and 6th weeks post-infection. Phenotyping the leukocytes into the spleen, TLR9-/- mice presented reduced neutrophils when compared to WT. Likewise, imunohistochemistry analyses showed the reduced of 7/4+ cells (specific to neutrophils) staining into the TLR-9-/- liver. The failure of neutrophil migration is not associated to their stage of activation impaired, but due the reduced levels of CXCL1 (KC) and CXCL2 (MIP-2) (neutrophil chemoatracttant) produced into into the spleen cells culture from infected TLR9-/-. Furthermore, DCs from TLR9-/- presented a semi-mature stage during in vitro and in vivo L. infantum infection, showing reduced expression of MHC-II and co-stimulatory molecule. Interestingly, the ability of DC to produce the neutrophil chemotact mediators (KC and MIP-2) was completely reduced by that derived from TLR9-/- mice, affecting neutrophil migration into Boyden chamber. Altogether, we demonstrated that TLR9 presents a critical role in the protective response against L.infantu through the mechanism dependent of crosstalk between neutrophil recruitment and DC activation.

L'infection chronique par le virus de l’hépatite B (HBV) est un problème de santé majeur dans le monde et peut conduire à la cirrhose et à l’hépatocarcinome. Des réponses défectives des cellules T ont été démontrées, mais les événements précis qui peuvent contribuer à l'insuffisance des réponses des cellules B restent à déterminer. L'expansion et la différenciation optimales des cellules B reposent sur l'activité du récepteur Toll Like Receptor 9 (TLR9) qui détecte l'ADNdb et est exprimée chez l'homme principalement par les cellules dendritiques plasmacytoïdes (pDC) et les cellules B. L'impact de HBV sur TLR9 dans les cellules B humaines reste à explorer. Dans cette étude, nous avons exploré les effets de HBV sur l’expression et les fonctions médiées par TLR9 dans les cellules B humaines en utilisant une lignée cellulaire de cellules B ainsi que des lymphocytes B primaires. De plus, on a corroboré nos résultats dans une cohorte de patients HBV chroniques. L'expression de TLR9 a été réduite chez les toutes les sous-populations de cellules B du sang périphérique, exposées au VHB. Les fonctions des cellules B médiées par TLR9 comme la prolifération et la sécrétion de cytokines pro-inflammatoires ont été abrogées en présence de HBV. Nos résultats montrent que l’antigène de surface HBsAg inhibe la phosphorylation du facteur de transcription CREB qui ne peut plus se lier sur son site CRE situé sur le promoteur TLR9 ce qui affecte la transcription de ce dernier. Enfin, nous avons corroboré nos résultats in vitro dans une cohorte de porteurs chroniques du HBV et constaté que l'expression et la fonction de TLR9 étaient significativement diminuées. Nos résultats révèlent le mécanisme qui induit une réponse immunosuppressive par HBV sur la fonction TLR9 dans les cellules B humaines, ce qui peut contribuer à la persistance de ce virus chez l'hôte et la complication de la phase chronique de la maladie / Chronic HBV infection is a major health problem worldwide. Ineffective T cell and antibody responses have been demonstrated, yet the precise events that may contribute to insufficient B cell responses remain to be determined. Optimal B cell function, expansion and differentiation rely on Toll Like Receptor 9 (TLR9) activity which senses dsDNA and is expressed in human mainly by plasmacytoid dendritic ( pDC) and B cells. The impact of HBV on TLR9 in human B cell subsets remains to be explored.Here, we investigated the effects of HBV on TLR9 function in human B cells. Both primary and B cell lines were used to analyze the effect of HBV on TLR9 expression and function. These results were corroborated in a cohort of chronically infected HBV patients. TLR9 expression was reduced in all peripheral blood B cells subsets exposed to HBV. B cell function mediated by TLR9, such as proliferation and pro-inflammatory cytokines secretion were abrogated in the presence of HBV. Our results show that the viral surface antigen HBsAg inhibited the phosphorylation of the transcription factor CREB which could no longer bind the CRE site located on the TLR9 promoter. Finally, we corroborated our in vitro findings in a cohort of chronic HBV carriers (CHB) and found that TLR9 expression and function were significantly suppressed.Our findings reveal the mechanism that induces an immunosuppressive response by HBV on TLR9 function in human B cells, which may contribute to HBV persistence in the host

Les virus du papillome humain (HPV) sont des virus à ADN double-brin encapsidés appartenant à la famille des Papillomaviridae ayant un tropisme distinct pour les épithéliums squameux de type muqueux ou cutanés. Jusqu'à présent, plus de 200 types de HPV ont été isolés et regroupés dans un arbre phylogénétique composé de 5 genres nommés alpha, beta, gamma, mu et nu. Parmi eux, les types HPV muqueux à haut risque appartenant au genre alpha ont été associés au cancer du col de l'utérus ainsi qu'à des sous-groupes de carcinomes ano-génitaux et de la tête et du cou. Ces virus sont responsables d'environ 5% de tous les cancers viro-induits. Les types bêta du HPV ont un tropisme pour la peau et pourraient être impliqués dans le développement du cancer de la peau non mélanique (NMSC), en association avec la lumière ultraviolette (UV). Ainsi, les modèles expérimentaux in vitro et in vivo ont démontré les propriétés de transformation des oncoprotéines E6 et E7 du type HPV bêta 38. De plus, des études sur le modèle de souris transgénique, où E6 et E7 du HPV38 sont exprimés au niveau de la couche basale non différenciée de l'épithélium sous le contrôle du promoteur du gène humain de la kératine (K14), ont montré une très forte susceptibilité de la peau à la carcinogenèse induite par les UV par rapport aux animaux de type sauvage. Tout aussi important que leur capacité à promouvoir la transformation cellulaire, les virus oncogènes ont développé différentes stratégies pour prendre le dessus sur le système immunitaire de l'hôte, favorisant ainsi l'établissement d'une infection persistante. Par conséquent, savoir si des virus oncogènes potentiels ont la capacité d'interférer avec la réponse immunitaire pourrait fournir des preuves supplémentaires de leur implication dans la cancérogenèse humaine. Ici, nous montrons que les oncoprotéines E6 et E7 de HPV38 suppriment l'expression de Tolllike 9 (TLR9), récepteur des ADN double-brins, en favorisant l'accumulation de ΔNp73α, un antagoniste de p53 et p73. Des expériences d'immunoprécipitation de la chromatine ont montré que ΔNp73α fait partie d'un complexe de régulation négative transcriptionnelle qui se lie à un élément de réponse NF-kappaB dans le promoteur TLR9. Fait intéressant, l'expression ectopique de TLR9 dans des cellules HPV38 E6E7 a entraîné une accumulation des inhibiteurs du cycle cellulaire p21WAF1/Cip1 et p27kip1, une réduction de l'activité kinase associée à CDK2 et l'inhibition de la prolifération cellulaire. Ensemble, ces données indiquent que TLR9 est impliqué dans d'autres événements, en plus de la réponse immunitaire innée. Par conséquent, nous avons constaté que le traitement des kératinocytes humains primaires (HPK) avec différents stress cellulaires, par exemple l'irradiation aux UV, la doxorubicine et le traitement H2O2, conduisent à une induction de la transcription de TLR9. Cet évènement induit par les UV est arbitré par le recrutement de plusieurs facteurs de transcription sur le promoteur TLR9, tels que p53, NF-kappaB p65 et c-Jun. L'expression de E6 et E7 de HPV38 affecte fortement le recrutement de ces facteurs de transcription sur le promoteur TLR9, avec comme conséquence l'affaiblissement de l'expression du gène TLR9. En résumé, nos données montrent que HPV38, de manière similaire à d'autres virus avec une activité oncogénique bien connue, peut inhiber 'expression de TLR9. Plus important encore, nous mettons en évidence une nouvelle fonction de TLR9 dans le contrôle de la réponse cellulaire aux stress et nous montrons que E6 et E7 de HPV38 sont capables d'interférer avec un tel mécanisme. Ces résultats confirment le rôle des types HPV bêta dans la carcinogenèse de la peau, en fournissant des informations supplémentaires sur leur contribution précise dans le processus multi-étapes de développement du cancer / The human papillomaviruses (HPV) consist of a group of capsid-enclosed double-stranded deoxyribonucleic acid (dsDNA) viruses from the Papillomaviridae family that display a distinct tropism for mucosal or cutaneous squamous epithelia. Until now, more than 200 types of HPV have been isolated and grouped into a phylogenetic tree composed of 5 genera (alpha, beta, gamma, mu and nu papillomaviruses). Among them, the mucosal high-risk HPV types that belong to the genus alpha have been associated with cervical cancer as well as a subset of anogenital and head and neck carcinomas. They are responsible for approximately 5% of all virus-induced cancers. Beta HPV types have a skin tropism and have been suggested to be involved, together with ultraviolet light (UV), in the development of non-melanoma skin cancer (NMSC). For instance, in vitro and in vivo experimental models highlight the transforming properties of beta HPV38 E6 and E7. Specifically, studies of transgenic mouse model, where HPV38 E6 and E7 are expressed in the undifferentiated basal layer of epithelia under the control of the Keratin 14 (K14) promoter, showed a very high susceptibility to UV-induced skin carcinogenesis in comparison to the wild-type animals. Equally important as their ability to promote cellular transformation, oncogenic viruses have different strategies to overtake the host immune system thus guaranteeing persistent infection. Therefore, understanding whether potential oncogenic viruses have the ability to interfere with the immune response could provide additional evidence relating to their involvement in human carcinogenesis. Here, we show that the E6 and E7 oncoproteins from HPV38 suppress the expression of the dsDNA innate immune sensor Toll-like receptor 9 (TLR9) by promoting the accumulation of ΔNp73α, an antagonist of p53 and p73. Chromatin immunoprecipitation experiments showed that ΔNp73α is part of a negative transcriptional regulatory complex that binds to a NF-κB responsive element within the TLR9 promoter. Interestingly, ectopic expression of TLR9 in HPV38 E6E7 cells resulted in an accumulation of the cell cycle inhibitors p21WAF/Cip1 and p27Kip1, reduction of CDK2-associated kinase activity and inhibition of cellular proliferation. Together these data indicate that TLR9 is involved in additional events, besides the innate immune response. Accordingly, we observed that the treatment of human primary keratinocytes (HPKs) with different cellular stresses, e.g. UV irradiation, doxorubicin and H2O2 treatment, results in TLR9 up-regulation. This UVinduced event is mediated by the recruitment of several transcription factors to the TLR9 promoter, such as p53, NF-kB p65 and c-Jun. The expression of HPV38 E6 and E7 strongly affect the recruitment of these transcription factors to the TLR9 promoter, with consequent impairment of TLR9 gene expression. In summary, our data show that HPV38, similarly to other viruses with well-known oncogenic activity, can down-regulate TLR9. Most importantly, we highlight a novel function of TLR9 in controlling the cellular response to stresses and we show that HPV38 E6 and E7 are able to interfere with such mechanism. These findings further support the role of beta HPV types in skin carcinogenesis, providing additional insight into their precise contribution to the multistep process of cancer development

Le cancer représente la deuxième cause de mortalité dans les pays industrialisés. Il a été démontré que 20% des cancers sont d'origine infectieuse. Nous nous sommes intéressés à deux oncovirus HPV (virus du papillome humain) et EBV (Epstein-Barr Virus) responsable du cancer de l'utérus et de divers lymphome B réciproquement. Les événements clés pour le développement d'un cancer viro-induit sont la persistance du virus via la dérégulation des réponses immunitaires et l'induction d'une instabilité gé¬nomique via une dérégulation du cycle cellulaire. Nous avons donc cherché si EBV était capable d'altérer la réponse immunitaire innée. Nous avons montré que EBV était capable d'inhiber TLR9 un acteur clef de la réponse immunitaire innée. Comme TLR9 est inhibé dans un certain nombre de cancers, nous nous sommes demandé si ce récepteur pouvait également, avoir un rôle dans l'oncogenèse. Nous avons montré que la réexpression de TLR9 induisait un ralentissement transitoire de la prolifération cellulaire. Nous nous sommes par la suite intéressés aux mécanismes de dérégulation du cycle cellulaire induits par E6 une oncoprotéine de HPV16. Nous avons trouvé un nouveau mécanisme d'inhibition de l'inhibiteur du cycle cellulaire, p21. HPV16E6 se lie et inhibe les fonctions de du facteur de transcription p150Sal2, ce qui induit une inhibition de p21 dans un contexte p53 indépendant / Cancer represents the second most common cause of death in industrialized countries. Epidemiological and biological studies have now conclusively proved that a variety of infectious agents constitute one of the main causes of cancer worldwide. It has been pointed out that more than 20% of cancers are from infectious origin. HPV high-risk mucosal types are associated to 98% of all cervical cancer cases. Regarding EBV, over 90% of the world’s population is infected and can give rise to malignancies such as Burkitt lymphoma or Hodgkin disease.(Young and Rickinson 2004) Keys features for oncoviruses to induce cancer are firstly to per¬sist by dampening host immune responses and to induce genomic instability in the host by altering the regulation of the cell cycle leading the infected cells to an uncontrolled proliferation. The purpose of this thesis was to find new mechanisms by which EBV and HPV can promote carcinogenesis. We have shown that EBV can alter the regulation and expression of TLRs, the key effectors molecules of the innate immune response. EBV infection of human primary B cells resulted in the inhibition of TLR9 functionality. Our study described a mechanism used by EBV to suppress the host immune response by deregulating the TLR9 transcript through LMP1-mediated NF-κB activation. As TLR was found deregulated in many cancers, we hypothesized that TLR9 may also a direct role in the process of cell cycle control and that loss of its expression may lead to transformation of the cell. Our overall objective here was to study the role of TLR9 in suppressing the events that initiates transformation of epithelial cells in the setting of cervical cancer (virus-associated) and in head and neck cancer (non–virus-associated). A third project dealt with the mechanism cell cycle deregulation by the oncoprotein E6 which expressed during infection with HPV16. We reported that HPV16E6 targets the cellular factor p150Sal2, which positively regulates p21 transcription. HPV16E6 associates with p150Sal2, inducing its functional inhibition by preventing its binding to cis elements on the p21 promoter. These data described a novel mechanism by which HPV16E6 induces cell cycle deregulation with a p53-independent pathway preventing G1/S arrest and allowing cellular proliferation and efficient viral DNA replication

Grado de magíster en fisiología / La obesidad, condición caracterizada por la presencia de un estado inflamatorio crónico, está estrechamente relacionada al desarrollo de diabetes tipo 2 (DM2), patología de alta prevalencia en individuos sedentarios. Se sabe que la actividad física regular es una de las medidas más eficaces para evitar los efectos deletéreos asociados a la obesidad y DM2, ya que además de reducir la actividad proinflamatoria, induce un ambiente antiinflamatorio. Proponemos en nuestra investigación que el entrenamiento de fortalecimiento muscular generará una disminución de la respuesta inflamatoria en la que participa el receptor de respuesta inmune TLR9, en un modelo de ratas obesas y DM2. Para tales efectos 8 ratas Wistar, macho, adultas, obesas y diabéticas fueron sometidas a un programa de entrenamiento de fortalecimiento muscular por 12 semanas (grupo entrenado (GE)), mediante el agarre, en sentido vertical, a una rejilla, por un tiempo predeterminado y con una carga externa sujeta a sus colas. 7 ratas de iguales características, no sometidas al entrenamiento, sirvieron como grupo control (GC). Al término del programa, se evaluó la fuerza muscular (tiempo máximo de agarre (segundos) sin carga externa) en todas las ratas. Luego, estas fueron sometidas a eutanasia y se cuantificó en el bazo la expresión del mRNA de genes implicados en la cascada de señalización de TLR9 y en la inducción de citokinas pro y antiinflamatorias. En el suero sanguíneo, se valoró la actividad inflamatoria sistémica por medio de la cuantificación de citokinas pro y antiinflamatorias y además, se midió la presencia de cfDNA (DNA de doble cadena, libre), ligando endógeno de TLR9. Adicionalmente, se midió masa corporal y grasa, parámetros de control glicémico y lipídico. En relación al GC, el GE mostró mayor fuerza muscular (47[16-139] segundos v/s 18 [10-22] segundos; p=0,01). Del total de ratas del GE, aquella mitad con valores de fuerza por sobre la mediana del grupo, las denominamos "respondedoras" (GR) al entrenamiento, mientras que al resto, las denominamos "subrespondedoras"(GSR). El GR mostró mayor fuerza respecto del GC y del GSR, presentando también una disminución significativa de su masa corporal respecto a los otros grupos. Además, el GR presentó menores valores en la expresión del mRNA de las citokinas proinflamatorias, TNF-α e IL-6, y de la proteína TNF-α valorada en el suero sanguíneo. No observamos modificaciones en la expresión del mRNA y proteína de la citokina antiinflamatoria IL-10. Por otra parte, se encontró en el GR una disminución significativa de la expresión de mRNA de las moléculas implicadas en la vía de señalización del receptor TLR9, así como menores concentraciones de cfDNA. Asociado a estos hallazgos, se observó en este grupo, menores valores en los parámetros metabólicos de control glicémico y mejoras en su perfil lipídico. En resumen, ratas obesas y diabéticas tratadas con un programa de entrenamiento de fortalecimiento muscular y que logran un aumento significativo en su fuerza muscular, presentan cambios también significativos en su composición corporal, marcadores metabólicos y de inflamación sistémica, así como una regulación negativa de la vía de señalización del receptor TLR9. Esto sugiere la necesidad de considerar las diferencias individuales en la capacidad de respuesta al entrenamiento de fortalecimiento muscular, al momento de su prescripción en pacientes obesos y diabéticos. / Obesity, a condition characterized by the presence of a chronic inflammatory state, is closely related to the development of type 2 diabetes (T2D), a pathology of high prevalence in sedentary individuals. It is known that regular physical activity is one of the most effective measures to avoid the deleterious effects associated with obesity and T2D, since in addition to reducing proinflammatory activity, it induces an anti-inflammatory environment. We propose in our research that muscle strengthening training will generate a decrease in the inflammatory response in which the immune response receptor TLR9 participates, in a model of obese rats and T2D. For this purpose 8 Wistar rats, male, adult, obese and diabetic rats were subjected to a muscle strengthening training program for 12 weeks (trained group (GE)), by gripping vertically to a grid, for a predetermined time and with an external load attached to their tails. 7 rats with the same characteristics, not subjected to training, served as a control group (CG). At the end of the program, muscle strength (maximum holding time (seconds) without external load) was evaluated in all rats. Then, they were euthanized and quantified in spleen the mRNA expression of genes involved in the TLR9 signaling cascade and induction of pro and anti-inflammatory cytokines. In the blood serum, the systemic inflammatory activity was assessed by means of the quantification of pro and anti-inflammatory cytokines and, in addition, the presence of cfDNA (free double-stranded DNA), endogenous ligand of TLR9, was measured. Additionally, body mass and fat, glycemic and lipid control parameters were measured. In relation to GC, the GE showed greater muscle strength (47 [16-139] seconds v / s 18 [10-22] seconds, p = 0.006). Of all the GE rats, which half with force values above the group median, we call them “responders” (GR) to training, while the rest, we call them "subresponders" (GSR). The GR showed greater strength with respect to the GC and the GSR, also presenting a significant decrease in their body mass with respect to the other groups. In addition, the GR presented lower values in the mRNA expression of the proinflammatory cytokines, TNF-αand IL-6, and TNF-α protein valued in the blood serum. We did not observe modifications in the mRNA and protein expression of the anti-inflammatory cytokine IL-10. On the other hand, a significant decrease in the mRNA expression of the molecules involved in the TLR9 signaling pathway was found in the GR, as well as lower concentrations of cfDNA. Associated with these findings, we observed in this group, lower values in the metabolic parameters of glycemic control and improvements in their lipid profile. In summary, obese and diabetic rats treated with a muscular strengthening training program that achieve a significant increase in their muscular strength, present also significant changes in their body composition, metabolic markers and systemic inflammation, as well as a negative regulation of the signaling path of the TLR9 receiver. This suggests the need to consider individual differences in the capacity to respond to muscle strengthening training, at the time of prescription in obese and diabetic patients.

One of the fundamental questions in mucosal immunology is how the intestine maintains tolerance to food antigens and commensal flora, and yet it is capable of mounting immune responses to pathogens. Peyers patches (PP) are lymphoid aggregates that are found in the small intestine and are the primary sites where adaptive immune responses are initiated in the intestine. An understanding of how PP cells regulate innate immune responses may provide information on how immune responses are regulated in the intestine. The toll-like receptors (TLRs) are a family of pattern recognition receptors (PRR) which provide a sensory mechanism for the detection of infectious threats. TLR9 recognizes bacterial DNA or synthetic CpG oligodeoxynucleotides (ODN). Cells that express TLR9 when stimulated with CpG ODN proliferate and produce Th1-like pro-inflammatory cytokines and upregulate co-stimulatory molecules. Because the intestine is constantly exposed to bacterial DNA from commensal flora, immune cells from the gut must have evolved mechanisms to modulate responses to TLR9 stimulation to prevent responses to harmless bacteria. Our hypothesis is that innate immune responses to the TLR9 agonist CpG ODN in Peyers patches (PP) are attenuated compared to other tissues such as blood or lymph nodes. This is due to local regulatory mechanisms unique to the intestinal microenvironment.<p> We conducted a number of experiments to test this hypothesis. We initially assessed the immunostimulatory activity of three available classes of CpG ODN in lymph nodes (LN), peripheral blood mononuclear cells (PBMC) and PP since this had not been done in ruminants. We found that CpG ODN induced strong IFNá, IFN-gamma, IL-12, lymphocyte proliferation and NK-like activity in LN and PBMC. In contrast, these responses were significantly less in PP stimulated with CpG ODN. We wondered whether the reduced responses of PP cells to CpG ODN were unique to the TLR9 agonist. For this reason we tested responses of cells from these tissues to poly (I:C), LPS, and single-stranded RNA, which are agonists for TLR3, TLR4, and TLR7/8 respectively. Additionally, we tested combinations of TLRs since others have reported that multiple TLR agonists may induce synergistic responses. All TLR agonists or their combinations either failed to induce detectable responses or the responses were significantly less in PP compared to other tissues. Thus we concluded that PP cells responses to TLR stimulation were attenuated. In all tissues tested, there were no synergistic responses (IFN-alpha, IFN-gamma and lymphocyte proliferation) following stimulation with combinations of agonists. However, there was inhibition of PBMC responses when TLR7/8 agonists were combined with CpG ODN (TLR9 agonist). Importantly, TLR7/8 agonists reduced the CpG-induced proliferative responses in purified blood B cells. Interestingly, ovine B cells constitutively expressed TLR7/8 and TLR9 mRNA, suggesting the potential for cross-talk between the receptors.<p> Interestingly, cell from all isolated tissues [ileal PP (IPP), jejunal PP (JPP), mesenteric LN (mLN) and PBMC] expressed similar levels of TLR9 mRNA, suggesting that the reduced responsiveness to CpG ODN stimulation in PP was not due to a lack of TLR9 expression.<p> Surprisingly, we observed that PP cells spontaneously secreted significant amounts of the immunoregulatory cytokine IL-10. Furthermore, we confirmed that CD21+ B cells were the source of the IL-10. We then examined the role of IL-10 in regulating IFN and IL-12 responses in PP. Neutralization of IL-10 resulted in a significant increase in the numbers of CpG-induced IFNá-secreting cells detected and in IFN-gamma and IL-12 production by PP cells (both follicular and interfollicular lymphocytes). Similarly, depletion of the CD21+ B cells resulted in significant increases in IFNá, IFN-gamma and IL-12 responses. These observations support the conclusion that IL-10-secreting PP CD21+ B cells suppress innate immune responses in PP. Further characterization by flow cytometry revealed that these cells were CD1b-CD5-CD11c-CD72+CD21+ IgM+ B cells. We have proposed that these IL-10-secreting PP CD21+ B cells are a novel subset of regulatory B cells (Bregs).<p> Finally, we examined the capacity of IL-10 secreting B cells (Bregs) to respond to CpG ODN. To achieve this, we compared CD21+ B cells from blood and JPP. Unlike blood CD21+ B cells, CD21+ B cells from JPP proliferated poorly in response to CpG ODN. Moreover, PP CD21+ B cells, unlike blood CD21+ B cells, do not secrete IgM or IL-12 in response to CpG stimulation, although both PP and blood CD21+ B cells express similar level of TLR9 mRNA. Neutralization of IL-10 did not enhance CpG-induced proliferative responses in PP CD21+ B cells. Thus IL-10 does not play a direct role in the hyporesponsiveness of PP CD21+ B cells to CpG ODN. To further explore the mechanism by which PP Bregs fail to respond to CpG ODN stimulation, we used a kinome analysis to determine whether the TLR9 pathway was functional in PP Bregs compared to blood CD21+ B cells. We observed that peptides representing critical adaptor molecules downstream of TLR9 such as IRAK1, TAK1, Casp8, p-38 MAPK, JNK, FOS, IKKá, NF-KB-p65 were not phosphorylated in JPP CD21+ B cells following CpG ODN stimulation. However, in blood CD21+ B cells stimulated with CpG ODN, the same peptides on the array were all highly phosphorylated leading to a functional TLR9 signaling pathway. Thus PP Bregs have evolved mechanisms by which the TLR9 signaling pathway is not activated following exposure to the TLR9 agonist, CpG ODN.<p> In conclusion, we clearly demonstrated that TLR9-induced responses in cells from PP are significantly attenuated. This is a consequence of PP CD21+ B cells (Bregs) that spontaneously secrete IL-10, which in turn conditions an anti-inflammatory environment in this tissue leading to poor cytokine responses to the TLR9 agonist, CpG ODN. Additionally, we show that Bregs are unresponsiveness to TLR9 stimulation. This unresponsiveness is due to regulatory mechanisms in Bregs leading to a dysfunctional TLR9 signaling pathway. These may represent strategies by which PP dampen innate responses to pathogen-associated molecular patterns (PAMPs) in intestinal immune tissues to maintain intestinal immune homeostasis. These conclusions are consistent with our hypothesis that TLR responses in PP cells are attenuated, and this is due to B cell-mediated regulatory mechanisms that are unique to the intestinal microenvironment.

One of the fundamental questions in mucosal immunology is how the intestine maintains tolerance to food antigens and commensal flora, and yet it is capable of mounting immune responses to pathogens. Peyers patches (PP) are lymphoid aggregates that are found in the small intestine and are the primary sites where adaptive immune responses are initiated in the intestine. An understanding of how PP cells regulate innate immune responses may provide information on how immune responses are regulated in the intestine. The toll-like receptors (TLRs) are a family of pattern recognition receptors (PRR) which provide a sensory mechanism for the detection of infectious threats. TLR9 recognizes bacterial DNA or synthetic CpG oligodeoxynucleotides (ODN). Cells that express TLR9 when stimulated with CpG ODN proliferate and produce Th1-like pro-inflammatory cytokines and upregulate co-stimulatory molecules. Because the intestine is constantly exposed to bacterial DNA from commensal flora, immune cells from the gut must have evolved mechanisms to modulate responses to TLR9 stimulation to prevent responses to harmless bacteria. Our hypothesis is that innate immune responses to the TLR9 agonist CpG ODN in Peyers patches (PP) are attenuated compared to other tissues such as blood or lymph nodes. This is due to local regulatory mechanisms unique to the intestinal microenvironment.<p> We conducted a number of experiments to test this hypothesis. We initially assessed the immunostimulatory activity of three available classes of CpG ODN in lymph nodes (LN), peripheral blood mononuclear cells (PBMC) and PP since this had not been done in ruminants. We found that CpG ODN induced strong IFNá, IFN-gamma, IL-12, lymphocyte proliferation and NK-like activity in LN and PBMC. In contrast, these responses were significantly less in PP stimulated with CpG ODN. We wondered whether the reduced responses of PP cells to CpG ODN were unique to the TLR9 agonist. For this reason we tested responses of cells from these tissues to poly (I:C), LPS, and single-stranded RNA, which are agonists for TLR3, TLR4, and TLR7/8 respectively. Additionally, we tested combinations of TLRs since others have reported that multiple TLR agonists may induce synergistic responses. All TLR agonists or their combinations either failed to induce detectable responses or the responses were significantly less in PP compared to other tissues. Thus we concluded that PP cells responses to TLR stimulation were attenuated. In all tissues tested, there were no synergistic responses (IFN-alpha, IFN-gamma and lymphocyte proliferation) following stimulation with combinations of agonists. However, there was inhibition of PBMC responses when TLR7/8 agonists were combined with CpG ODN (TLR9 agonist). Importantly, TLR7/8 agonists reduced the CpG-induced proliferative responses in purified blood B cells. Interestingly, ovine B cells constitutively expressed TLR7/8 and TLR9 mRNA, suggesting the potential for cross-talk between the receptors.<p> Interestingly, cell from all isolated tissues [ileal PP (IPP), jejunal PP (JPP), mesenteric LN (mLN) and PBMC] expressed similar levels of TLR9 mRNA, suggesting that the reduced responsiveness to CpG ODN stimulation in PP was not due to a lack of TLR9 expression.<p> Surprisingly, we observed that PP cells spontaneously secreted significant amounts of the immunoregulatory cytokine IL-10. Furthermore, we confirmed that CD21+ B cells were the source of the IL-10. We then examined the role of IL-10 in regulating IFN and IL-12 responses in PP. Neutralization of IL-10 resulted in a significant increase in the numbers of CpG-induced IFNá-secreting cells detected and in IFN-gamma and IL-12 production by PP cells (both follicular and interfollicular lymphocytes). Similarly, depletion of the CD21+ B cells resulted in significant increases in IFNá, IFN-gamma and IL-12 responses. These observations support the conclusion that IL-10-secreting PP CD21+ B cells suppress innate immune responses in PP. Further characterization by flow cytometry revealed that these cells were CD1b-CD5-CD11c-CD72+CD21+ IgM+ B cells. We have proposed that these IL-10-secreting PP CD21+ B cells are a novel subset of regulatory B cells (Bregs).<p> Finally, we examined the capacity of IL-10 secreting B cells (Bregs) to respond to CpG ODN. To achieve this, we compared CD21+ B cells from blood and JPP. Unlike blood CD21+ B cells, CD21+ B cells from JPP proliferated poorly in response to CpG ODN. Moreover, PP CD21+ B cells, unlike blood CD21+ B cells, do not secrete IgM or IL-12 in response to CpG stimulation, although both PP and blood CD21+ B cells express similar level of TLR9 mRNA. Neutralization of IL-10 did not enhance CpG-induced proliferative responses in PP CD21+ B cells. Thus IL-10 does not play a direct role in the hyporesponsiveness of PP CD21+ B cells to CpG ODN. To further explore the mechanism by which PP Bregs fail to respond to CpG ODN stimulation, we used a kinome analysis to determine whether the TLR9 pathway was functional in PP Bregs compared to blood CD21+ B cells. We observed that peptides representing critical adaptor molecules downstream of TLR9 such as IRAK1, TAK1, Casp8, p-38 MAPK, JNK, FOS, IKKá, NF-KB-p65 were not phosphorylated in JPP CD21+ B cells following CpG ODN stimulation. However, in blood CD21+ B cells stimulated with CpG ODN, the same peptides on the array were all highly phosphorylated leading to a functional TLR9 signaling pathway. Thus PP Bregs have evolved mechanisms by which the TLR9 signaling pathway is not activated following exposure to the TLR9 agonist, CpG ODN.<p> In conclusion, we clearly demonstrated that TLR9-induced responses in cells from PP are significantly attenuated. This is a consequence of PP CD21+ B cells (Bregs) that spontaneously secrete IL-10, which in turn conditions an anti-inflammatory environment in this tissue leading to poor cytokine responses to the TLR9 agonist, CpG ODN. Additionally, we show that Bregs are unresponsiveness to TLR9 stimulation. This unresponsiveness is due to regulatory mechanisms in Bregs leading to a dysfunctional TLR9 signaling pathway. These may represent strategies by which PP dampen innate responses to pathogen-associated molecular patterns (PAMPs) in intestinal immune tissues to maintain intestinal immune homeostasis. These conclusions are consistent with our hypothesis that TLR responses in PP cells are attenuated, and this is due to B cell-mediated regulatory mechanisms that are unique to the intestinal microenvironment.

Bacterial DNA is immunostimulatory, and the motifs responsible for this activity are unmethylated CpG dinucleotides. Following cellular uptake, CpG-containing oligodeoxynucleotides (CpG ODN) are trafficked to the endosome where they bind Toll-like receptor 9 (TLR9) to initiate a signaling cascade that culminates in the release of numerous pro-inflammatory cytokines. Because of their immunostimulatory properties, CpG ODN are being clinically evaluated as treatments and vaccine adjuvants for infectious diseases, cancer, and allergic disorders. α2-Macroglobulin (α2M) is a human plasma protein that binds and modulates the activity of a variety of cytokines, growth factors, enzymes, and antigens. Upon proteolytic activation, α2M is converted to its receptor recognized form, α2M*, and rapidly binds to and is internalized by immune competent cells expressing the α2M* endocytic receptor, LRP, and is then trafficked to the endosome. Based on these interactions, α2M seems to play an important role at sites of infection and inflammation by controlling the level of proteinase activity, modulating cytokine signals, and enhancing antigen processing for the adaptive immune response. Here, we report the first evidence that α2M* binds and forms stable complexes with nucleic acids. We have characterized the mechanisms and stoichiometry of this interaction, examined the pH and temperature stability of these complexes, and identified structural variables in the nucleic acids, namely length, base composition, and chemical modifications, that affect the nature of this interaction. We hypothesized that CpG ODN incorporation into α2M* may alter their immunostimulatory properties. Murine macrophages (MΦs) treated with α2M*-ODN complexes respond more rapidly and produce a greater cytokine response than those treated with free CpG ODN alone. Treating human PBMCs with α2M*-ODN complexes likewise demonstrated their enhanced ability to elicit immune responses. This was due to more rapid uptake and CpG ODN protection from degradation by extracellular nucleases. Co-incorporation of both protein ligands and CpG ODN into α2M* yields ternary complexes; these may permit the simultaneous delivery of both protein antigens and adjuvants to immune competent cells, potentially greatly enhancing the adaptive immune response and protective immunity. Based on the findings that incorporation into α2M* confers enhanced immunostimulatory activity of CpG ODN, this technology may be exploited to improve CpG ODN-based therapeutics by increasing efficacy, minimizing side effects, reducing dosing requirements, and reducing cost. / Dissertation